Drug Trial Radar · NCT01722539
Impact IPT With Sulfadoxine-pyrimethamine or Sulfadoxine-pyrimethamine Plus Piperaquine in Schoolchildren
Last checked: Nov 20, 2026Latest source record: Feb 4, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
616
Actual
Start
Nov 2012
Primary completion
Nov 2013
Study completion Nov 2013
Sponsor
- Lead sponsor
- Universiteit AntwerpenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Fund for Scientific Research, Flanders, Belgium; University of Kinshasa
- First posted
- Nov 7, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 5 years, up to 14 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Considering the facts that: (i) IPT of malaria provides substantial protection against anaemia and malaria in school children (ii); SP resistance has no significant impact on the prophylactic efficacy (iii) SP-PQ is safe and as efficacious as SP: the investigators hypothesize that antimalarial IPT with SP and SP-PQ will improve haemoglobin concentration, reduce anaemia prevalence, malaria incidence and parasitaemia, and improve malnutrition and school performance in school-aged children of Congo.
Conditions
- Healthy
Interventions
Sulfadoxine-pyrimethamineDrug
Tablets 500 mg sulfadoxine - 25 mg pyrimethamine will be given as single oral dose of ½ tablets per 10 kg of weigh: 1 tablet for weigh less than 20 kg, 1.5 tablets in 20-29 kg, and 2 tablets for children of weigh 30 or more
PiperaquineDrug
Piperaquine tablet 320 mg manufactured by Sigma Tau will be used at two treatment doses of 16-24 mg/kg at 24 hours intervals as follows: 1 tablets for weigh 15-19 kg, 1.5 tablets for 20-29 kg, and 2 tablets for 30-39 kg, and 2.5 tablets for 40 kg or more.
AlbendazoleDrug
One oral 200 mg will be given to children of 1-2 years and one oral dose of 400 mg to children older than 2 years. The treatment will be repeated at 4-months in the follow-up in accordance with the WHO guideline.
PraziquantelDrug
Praziquantel is a tremacide used for treatment of infections due to schistosomes. Praziquantel will be given as one dose of 40 mg/kg at enrolment and at 12 months follow up.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Hemoglobin changeTime frame: Month 0-Month 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mokali health area of Biyela health zone, in Kinshasa province.
Kinshasa, Kinshasa Province, Republic of the Congo
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.